Foundayo vs. Zepbound®: Pill vs. Injection for Weight Loss

If you’ve been researching Foundayo vs Zepbound® and wondering the difference between the two, it’s understandable. Both are made by Eli Lilly. Both are approved for chronic weight management in adults. And both are showing up in the same conversations, forums, and search results.

But they’re not the same medication, and for many people, they’re not interchangeable. In fact, choosing between the GLP-1 pill vs injection question isn’t really about the format; it’s more about what each GLP-1 medication does inside your body, and what’s most appropriate for your individual situation.

Below, we take a closer look at how each medication works, what the clinical trial data shows about switching, who each option may suit, and what to bring up with your provider.

‍

What Is Foundayo?

Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist. It was approved by the FDA on April 1, 2026, for chronic weight management in adults with obesity, or adults with overweight who have at least one weight-related medical condition. And it’s meant to be used alongside a reduced-calorie diet and increased physical activity.

Orforglipron, the active ingredient in Foundayo, is a small-molecule, non-peptide drug. Unlike peptide-based GLP-1s, it’s absorbed without the strict timing and water conditions other oral options require. This is why it can be taken at any time of day, with or without food or water. 

‍

How Foundayo Works

As a single-receptor agonist, Foundayo activates only GLP-1 receptors, which are involved in appetite regulation. GLP-1 receptors help tell your body it’s full and slow the rate at which food leaves your stomach. 

‍

Foundayo Dosing and Format

Foundayo is taken as a tablet once daily, starting at 0.8 mg. It’s typically increased over several weeks, under proper provider supervision. It requires no refrigeration and no timing restrictions.

Like other medications in this class, gastrointestinal side effects are common and tend to be most pronounced during dose escalation.

‍

What Is Zepbound®?

Zepbound® (tirzepatide) is an injectable medication approved by the FDA for chronic weight management in adults and, separately, for moderate-to-severe obstructive sleep apnea in adults with obesity. It’s given as a subcutaneous injection once weekly and is available as single-dose prefilled pens, single-dose vials, and multi-dose pens.

When comparing Zepbound® vs. Mounjaro, it’s worth noting that tirzepatide is also the active ingredient in Mounjaro® (which is FDA-approved for type 2 diabetes). When researching GLP-1s, you may have come across it in this context.

‍

How Zepbound® Works

Zepbound® is a dual GIP and GLP-1 receptor agonist. This means that it activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and GLP-1 receptors at the same time.

In other words, it works on two separate appetite and metabolic pathways, which is why its clinical weight loss outcomes have generally exceeded those of single-receptor GLP-1 agonists.

In the SURMOUNT-5 trial, researchers reported that participants taking tirzepatide lost an average of 20.2% of body weight at 72 weeks compared with 13.7% for those taking semaglutide. However, results may vary from person to person.

‍

Zepbound® Dosing and Format

Zepbound® is injected under the skin once per week, typically starting at 2.5 mg and titrating (slowly increasing) upward. You’ll need to learn the proper injection technique, and most versions have to be kept in the fridge. 

If you’re scared or squeamish when it comes to needles, Zepbound® may not be right for you. And Foundayo may be a Zepbound® alternative for some patients, depending on their health history, treatment goals, and a licensed healthcare

provider’s clinical judgment. 

Foundayo vs Zepbound®: Key Differences at a Glance

Here’s how orforglipron vs tirzepatide compare side-by-side:

While on paper these differences look straightforward, clinically, they’re more nuanced. This is especially true if you’re already on one of these medications and intending to switch. Stopping or switching medications should never be done without consulting a licensed provider first.

‍

What the Clinical Data Shows About Switching

In the ATTAIN-MAINTAIN Phase 3 trial, researchers took 376 adults who had already lost meaningful weight on either Wegovy® (semaglutide) or Zepbound® (tirzepatide) injections during the SURMOUNT-5 trial. They split the group in two: half took a once-daily orforglipron pill, and the other half took a placebo for 52 weeks. Researchers aimed to determine if the pill could maintain the participants’ previous results.

Participants who had lost an average of about 40.7 lbs on semaglutide injections regained roughly 2 lbs—about 5% of what they’d lost—after switching to orforglipron. In other words, moving from the semaglutide injection to the pill didn’t significantly change their results.

On the other hand, researchers reported that participants who had lost an average of about 54.8 lbs on tirzepatide injections regained roughly 11 lbs, which is about 20% of what they’d lost.

So, why the gap? 

Simply put, moving from a dual-receptor agonist to a single GLP-1 receptor agonist isn’t a lateral step. A single-receptor pill can’t replicate dual-receptor potency.

Obesity specialist Dr. Beverly Tchang advised that patients transitioning from semaglutide injections may reasonably switch to Foundayo. Meanwhile, patients on tirzepatide should generally remain on tirzepatide if they are achieving results.

In other words, if you’re on Zepbound® and losing weight, the data supports staying on it. Any decision to switch should be made with a licensed provider who can evaluate your individual situation.

‍

Who May Be a Candidate for Foundayo

At the end of the day, Foundayo isn’t right for everyone. But it may be an option for specific individuals, including:

• Those who don’t want to inject: For someone who would otherwise skip GLP-1 treatment entirely because of needle aversion, an effective oral weight loss medication may represent a meaningful benefit, even with a lower efficacy ceiling than Zepbound®.
• Those transitioning from semaglutide injections: The ATTAIN-MAINTAIN data suggests this is a comparatively low-risk transition.
• Those who prioritize simplicity in their routine: Foundayo is taken as a once-daily oral tablet and does not require refrigeration or injection supplies. If you’re managing a busy schedule or other timing-sensitive medications, a daily pill may support better long-term adherence.
• Those who haven’t started an injectable yet: If you’re new to GLP-1 medications and needle-averse, Foundayo may be an appropriate treatment option for some.

On top of the above, Foundayo requires a prescription. This means eligibility also depends on your health history, current medications, and a licensed healthcare provider’s assessment. 

‍

Who May Be a Candidate for Zepbound®

Zepbound® may be appropriate for:

• Those already achieving results on tirzepatide. The ATTAIN-MAINTAIN trial reports that switching introduces meaningful regain risk.
• Those with larger weight loss goals. The SURMOUNT-5 trial suggests the dual-receptor mechanism may support greater total weight loss than single-receptor GLP-1 medications, though individual results may vary.
• Those with obstructive sleep apnea. Zepbound® is FDA-approved for moderate-to-severe OSA in adults with obesity.
• Those comfortable with weekly dosing. You may prefer a once-weekly routine instead of remembering to take a daily pill.

In some circumstances, a licensed healthcare provider may determine that a compounded tirzepatide medication is appropriate for an identified patient based on a clinical need. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality. If prescribed, they are prepared and dispensed by licensed compounding pharmacies. 

‍

Side Effects: What to Expect From Each

Both medications share similar gastrointestinal side effects, which also tend to intensify during dose increases.

Foundayo side effects may include: 

• Nausea (26-35%)
• Constipation (20-27%)
• Diarrhea (21-25%)
• Vomiting (13-24%)
• Indigestion (12-16%)
• Stomach pain (13-14%)
• Headache (8-9%)
• Bloating (7-9%)
• Fatigue (6-9%)
• Hair loss (4-5%).

Zepbound® side effects may involve:

• Nausea (25-29%)
• Diarrhea (19-23%)
• Constipation (11-17%)
• Vomiting (8-13%)
• Stomach pain (9-10%)
• Indigestion (9-10%)
• Injection site reactions

Both carry similar serious warnings, including:

• Possible thyroid tumor risk based on animal studies
• Pancreatitis
• Gallbladder problems
• Kidney injury related to dehydration
• Low blood sugar
• Allergic reactions
• Diabetic retinopathy complications in people with type 2 diabetes
• Lung complications during general anesthesia or deep sedation

Some individuals have reported persistent bloating and returning appetite after switching medications. These anecdotal experiences are not a substitute for clinical evidence, but they are consistent with findings from the ATTAIN-MAINTAIN trial. 

If you experience any new or worsening symptoms, report them to your provider promptly; never adjust your dose or switch medications on your own.

‍

Talking to Your Provider: Questions to Bring to Your Next Visit

Knowing what to ask at your next appointment may make things a bit smoother. Here are a few questions you may want to consider with your provider:

1. Based on my weight, health history, and goals, which mechanism makes more sense for me?
2. If I’m on Zepbound® and considering Foundayo, what does the ATTAIN-MAINTAIN data mean at my stage of treatment?
3. Is there anything in my health history that would rule out either option?
4. What should I expect during dose escalation? And how do we manage GI side effects if they show up?
5. Is compounded tirzepatide an option for me? And how does it differ from brand-name Zepbound® in oversight and cost?

You may also want to use our BMI calculator to determine your starting point and potential eligibility.

At Eden, you can also get started with a quick online intake. Afterward, we connect you with a licensed healthcare provider who reviews your health history, goals, and lifestyle to determine which medication (if any) is the right fit.